Efficacy Analysis of High-flow Nasal Oxygen Therapy in Patients 
Accepting Single-port Video-assisted Thoracoscopic Lobectomy
In this study, the superiority-inferiority of different oxygen inhalation methods were compared with high-flow nasal oxygen therapy (HFNO), noninvasive mechanical ventilation (NIMV) and nasal oxygen breath (NOB) in patients with hypoxemia after single-port video-assisted thoracoscopic (VATS) lobectomy, and the clinical efficacy of HFNO in these patients was further investigated. Methods A total of 180 patients from the Second Affiliated Hospital of Soochow University in China with hypoxemia who accepting single-port VATS lobectomy from June 2021 to March 2022 were randomly divided into three groups (n=60), which were treat...
Source: Chinese Journal of Lung Cancer - September 20, 2022 Category: Cancer & Oncology Source Type: research

Chinese Expert Consensus on Management of Special Adverse Effects 
Associated with Lorlatinib
Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wide spectrum of multiple resistance mutations within the ALK domain detected during crizotinib and 2nd generation ALK TKI treatment. Lorlatinib is generally well-tolerated with unique adverse drug reaction/adverse event, including hyperlipidemia and central nervous system effects, which are mostly mild to moderate severity and ma...
Source: Chinese Journal of Lung Cancer - August 24, 2022 Category: Cancer & Oncology Source Type: research

Application and Research Progress of Video Double-lumen Tube in Thoracic Surgery
This article reviews the application and research progress of VDLT in thoracic surgery. 
 DOI: 10.3779/j.issn.1009-3419.2022.101.35 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research

Research Progress of Acquired Resistance Mediated by MET Amplification 
in Advanced Non-small Cell Lung Cancer
Mesenchymal-epithelial transition factor (MET) amplification is an important driver of resistance in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and the combination of MET proto-oncogene (MET) and EGFR-tyrosine kinase inhibitors (TKIs) has shown promise in overcoming this molecularly defined acquired resistance. Emerging data also demonstrate MET amplification as a resistance driver to TKIs-treated anaplastic lymphoma kinase (ALK)-, RET-, and ROS1-fusion NSCLC. Here, we review the literature on recent research progress of MET amplification as a resistance driver to targeted therapy in...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research

Research Progress on the Application of Liquid Biopsy in the Diagnosis 
and Treatment of Small Cell Lung Cancer
Small cell lung cancer (SCLC) is a malignant tumor with strong invasiveness and high mortality. It has the characteristics of easy metastasis, fast growth, high degree of malignancy and strong invasiveness. The prognosis of patients is generally poor. The current clinical diagnosis of SCLC is mainly based on tissue biopsy, which is invasive, long cycle time and high cost. In recent years, liquid biopsy has been gradually applied because of its non-invasive, comprehensive and real-time characteristics that traditional tissue biopsy does not have. The main detection objects of liquid biopsy include circulating tumor DNA (ctD...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research

Advances in ICIs Therapy after TKIs Resistance in Patients with EGFR Mutant NSCLC: A Review
The follow-up treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation after drug resistance to EGFR-tyrosine kinase inhibitors (TKIs) have become a hotspot and difficulty at present. Immune checkpoint inhibitors (ICIs) therapy is a new and important choice for these patients, but many studies have shown unsatisfactory efficacy. However, some domestic and foreign studies have shown that ICIs combination therapy is still effective in some patients with positive driver genes and drug resistance after targeted therapy. So, in the era of immunotherapy, what ar...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research

A Review on Pathological High-risk Factors and Postoperative Adjuvant Chemotherapy in Stage IA Lung Adenocarcinoma
This article is a review on the research progress of the above pathological high-risk factors and the role of adjuvant chemotherapy in patients with pathological high-risk factors in stage IA lung adenocarcinoma. 
 DOI: 10.3779/j.issn.1009-3419.2022.101.30 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research

Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated 
Advanced Non-small Cell Lung Cancer
Lung cancer is one of the leading causes of cancer-related morbidity and mortality. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have become the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Unfortunately, drug resistance is inevitable in most cases. EGFR-TKI combined with angiogenesis inhibitors is a treatment scheme being explored to delay the therapeutic resistance, which is called “A+T treatment”. Several clinical trials have demonstrated that the A+T treatment can improve the progression free survival (PFS) of the NSCLC patients. However, compared to EGFR...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research

Analysis of Clinicopathologic Features of 9 Cases of 
SMARCA4-deficient Non-small Cell Lung Cancer
Conclusion SMARCA4-dNSCLC is a rare subtype of lung cancer with complex and diverse pathological morphology. The characteristic of immunohistochemical phenotype can assist in the diagnosis. 
 DOI: 10.3779/j.issn.1009-3419.2022.102.27 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research

miR-30b-3p Inhibits the Proliferation and Invasion of Lung Adenocarcinoma 
by Targeting COX6B1
Background and objective Lung adenocarcinoma (LUAD) is the most common clinical histological subtype of lung cancer and microRNAs (miRNAs) are a type of small non-coding RNAs which play a central role in cells. miR-30b-3p plays a key effect in many types of carcinoma, but there is still very little research on how it works in lung adenocarcinoma. The role and mechanism of miR-30b-3p in the proliferation and invasion of LUAD were explored in this study, to provide new targets for inhibiting the proliferation and invasion of LUAD. Methods NCBI database was used to screen out miRNA with obvious differential expression, and th...
Source: Chinese Journal of Lung Cancer - August 20, 2022 Category: Cancer & Oncology Source Type: research

Consideration on the Research and Development of New Drugs for Rare Tumors
In recent years, China ' s anti-tumor drugs has shown a continuous growth trend, and the activity of anti-tumor research and development in China accounts for a higher proportion in the world. However, further analysis of research and development hotspots show that the research and development of anti-tumor drugs is uneven among different tumor types. Due to the small number of the patients, it is difficult to conduct clinical trials, resulting in less drug development in the field of rare tumors. However, patients ' treatment needs will also bring potential opportunities for pharmaceutical companies. The development of ba...
Source: Chinese Journal of Lung Cancer - July 27, 2022 Category: Cancer & Oncology Source Type: research

Clinical Observation of Immunotherapy Efficacy and Adverse Effects 
in Chinese Patients with Lung Squamous Cell Carcinoma
This study aimed to investigate the efficacy and toxicity of immunotherapy in patients with LUSC in Chinese population of real world. Methods A total of 185 LUSC patients underwent pathological diagnosis were involved from January 2018 to January 2022. Patients were divided into elderly group (age ≥70 years) and younger group (age0.05). Both combined group and immunology alone demonstrated prolonged mPFS in first-line compared with chemotherapy in elderly group. And combined group demonstrated significantly prolonged mPFS compared with chemotherapy in younger group (P (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research

Research Progress of Antitumor Pharmacovigilance
We described the difficulties in antitumor pharmacovigilance and current characteristics of pharmacovigilance in China, aiming to provide reference for the development of antitumor pharmacovigilance. 
 DOI: 10.3779/j.issn.1009-3419.2022.101.33 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research

Clinical Value of Autoantibody Prognostic Markers in Tumor Immune Checkpoint 
Inhibitor Therapy
Serum autoantibody markers have the advantages of easy specimen acquisition, simple detection technology and dynamic real-time monitoring. With the wide application of immune checkpoint inhibitors in the treatment of malignant tumors, autoantibody markers in predicting tumor immune checkpoint inhibitors efficacy and forecasting irAEs (immune related adverse events) show good prediction of potential. This review mainly focused on the progress of autoantibody markers in the prediction of therapeutic effect and the monitoring of irAE in tumor immunotherapy. 
 DOI: 10.3779/j.issn.1009-3419.2022.101.28 (Source: Chinese Journal of Lung Cancer)
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research

Progress of Neoadjuvant Immunotherapy for Non-small Cell Lung Cancer
Neoadjuvant immunotherapy, including neoadjuvant single- or dual-drug immunotherapy or combined immunotherapy with chemotherapy or radiotherapy, has witnessed a rapid development in non-small cell lung cancer. Clinical trials exhibited the encouraging pathological responses and certain clinical benefits in selected patients, with tolerable toxicity. Nivolumab with chemotherapy has been approved by Food and Drug Administration (FDA) as the first immunotherapy-based treatment for non-small cell lung cancer in the neoadjuvant treatment setting. There is the need for further evaluation of long-term efficacy, side effects or su...
Source: Chinese Journal of Lung Cancer - July 20, 2022 Category: Cancer & Oncology Source Type: research